Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 1, 2011, Pages 61-67

  Gugliucci, Alejandro ^a   Kinugasa, Eriko ^b   Kotani, Kazuhiko ^a,c   Caccavello, Russell ^a   Kimura, Satoshi ^a,b  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; HDL; Lipoperoxides; Paraoxonase; Renal failure

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CREATININE; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOTRIESTERASE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENDER; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; HEALTHY PEOPLE PROGRAMS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 79953145938     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.004     Document Type: Article

References (30)

1. Dikow R, Zeier M, Ritz E. Pathophysiology of cardiovascular disease and renal failure. Cardiol Clin 2005;23:311-7. (Pubitemid 41097353)
2. McCullough PA. Evaluation and treatment of coronary artery disease in patients with end-stage renal disease. Kidney Int Suppl 2005;S51-8. (Pubitemid 43361557)
3. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005;34:31-5. (Pubitemid 40379970)
4. Ritz E, Dikow R, Schwenger V, Gross ML. Hemodialysis - from early days to tomorrow. Contrib Nephrol 2005;149:1-9. (Pubitemid 43264995)
5. Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis. Chem Biol Interact 1993;87:161-71. (Pubitemid 23205375)
6. Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, et al. The PON1 gene and detoxication. Neurotoxicology 2000;21:581-7.
7. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119-120:379-88. (Pubitemid 29278574)
8. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-9. (Pubitemid 41017622)
9. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-16. (Pubitemid 39349234)
10. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 2010;660:113-27.
11. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657-65. (Pubitemid 43847536)
12. Tavori H, Khatib S, Aviram M, Vaya J. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg Med Chem 2008;16:7504-9.
13. Tavori H, Vaya J, Aviram M. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv Exp Med Biol 2010;660:99-111.
14. Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from DFPase like homology model. Biochim Biophys Acta 2004;1702:67-77. (Pubitemid 39265470)
15. Efrat M, Rosenblat M, Mahmood S, Vaya J, Aviram M. Dioleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis 2009;202:461-9.
16. Gaidukov L, Viji RI, Yacobson S, Rosenblat M, Aviram M, Tawfik DS. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry 2010;49:532-8.
17. Khersonsky O, Rosenblat M, Toker L, Yacobson S, Hugenmatter A, Silman I, et al. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization. Biochemistry 2009;48:6644-54.
18. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008;56:8704-13.
19. Efrat M, Aviram M. Paraoxonase 1 Interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. Adv Exp Med Biol 2010;660:153-66.
20. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999;83:126-31. (Pubitemid 29447506)
21. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-70. (Pubitemid 28458792)
22. Peti A, Csiky B, Guth E, Kenyeres P, Varga Z, Seres I, et al. Associations of adiponectin with paraoxonase 1 and sE-selectin in hemodialyzed patients. Kidney Blood Press Res 2009;32:360-5.
23. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004;17:813-8. (Pubitemid 41158301)
24. Biasioli S, Schiavon R, Petrosino L, De Fanti E, Cavalcanti G, Battaglia P. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. Asaio J 2003;49:295-9. (Pubitemid 36570151)
25. Hasselwander O, McEneny J, McMaster D, Fogarty DG, Nicholls DP, Maxwell AP. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis 1999;143:125-33. (Pubitemid 29138710)
26. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata, H. Hermo R. Schulze J. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007;377:213-20. (Pubitemid 44920216)
27. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta 2007;384:105-12. (Pubitemid 47260577)
28. Khersonsky O, Tawfik DS. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006;281:7649-56. (Pubitemid 43847535)
29. Khersonsky O, Tawfik DS. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem 2006;7:49-53. (Pubitemid 43076285)
30. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim Biophys Acta 2009;1790:155-60.